Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma

Traders Union
All News
Business & Wealth
Companies
Oric Pharmaceuticals up 1.60% today

Highlights

ORIC Pharmaceuticals trades below major moving averages, confirming a persistent bearish trend across all time frames.
Momentum and trend indicators show clear negative signals with weak buying activity, oversold conditions, and seller dominance.
The stock is consolidating just above the 52-week low, with the expected range at $7.00–$8.00 and low probability of upside reversal.

Listeners can access the discussion for the latest company updates online. The company shared a link for live access in its announcement.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bearish trend confirmed as price remains below all major averages

ORIC Pharmaceuticals is trading at $7.62, which is below all key moving averages: the SMA-20 at $8.34, SMA-50 at $9.42, and SMA-200 at $10.78. This confirms persistent bearish pressure across short-, medium-, and long-term trends. The Ichimoku Kijun at $8.73 stands above the current price and acts as immediate resistance. Near-term support is seen at the HMA ($7.61) and SMA-20 ($8.34), while key resistance levels are clustered at the Kijun ($8.73) and SMA-50 ($9.42).

Seller dominance persists as momentum indicators signal oversold conditions

Momentum signals on D1 remain clearly negative, with the MACD and ADX both indicating a lack of buying strength and weak trend conviction. Oversold conditions are evident in the CCI (-134.61), BBP (-0.10), and Stoch RSI (30.99), while the RSI at 35.75 implies sellers are in control but not at extreme levels. BBP and AO both reinforce seller dominance. In today's session, ORIC is up 1.60%, but this does little to change the broader view. Over the past week, ORIC has risen $0.12 (1.47%) from a prev_week_close of $7.50, with the price currently located in the lower part of the recent range. Weekly volatility stands at 13.52%. The price has retreated sharply from the weekly high and is consolidating just above the 52-week low.

Downside risks prevail as key trend indicators stay bearish

Looking ahead, the expected price range for the coming week is $7.00–$8.00, which brackets the current price and keeps it well within 20% of recent levels. The probability of a price increase is very low (less than 20%), with a price decline being much more likely, as all major W1 trend indicators (RSI, MACD, ADX, MA-50) remain bearish or neutral. The baseline scenario is continued sideways action near recent lows. A bullish scenario requires breaking above $8.73 (Kijun) with a possible move to $9.42 (SMA-50), but this is unlikely given the technical backdrop. A bearish breakdown below $7.32 could open the way toward new 52-week lows. This forecast range sits just above the current 52-week low of $7.32 and remains well below the 52-week high of $14.93, highlighting the persistent downtrend.

Earlier, analysts noted that Oric Pharmaceuticals was facing persistent bearish momentum amid heavy selling pressure. This article expands on that outlook by identifying the prevailing market scenario and highlighting the need to monitor for a decisive shift in sentiment as a catalyst for near-term positioning.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.